Effects of metabolic and myocardial microcirculatory abnormalities on the pathogenesis of cardiac autonomic neuropathy in type 2 diabetes mellitus: A prospective study in Japanese patients  by Komori, Hiromi
VIILUME 66, NUMBER 6, NIIVEMBER/DEc'EMBER 2005 
Effects of Metabolic and Myocardial 
Microcirculatory Abnormalities on the 
Pathogenesis of Cardiac Autonomic Neuropathy 
in Type 2 Diabetes Mellitus: A Prospective Study 
in Japanese Patients 
Hiromi Komori, MD 
Division of Diabetology, Department of Internal Medicine, Toho University, 
Ohashi Hospital, Tokyo, Japan 
ABSTRACT 
Background: In diabetic patients, cardiac autonomic neuropathy is an 
important factor affecting prognosis. Whether this condition in diabetic 
patients is caused directly by neurovisceral metabolic disorder and/or indi- 
rectly by microcirculation remains to be clarified. 
Objective: The aim of this study was to determine whether cardiac sympa- 
thetic nerve dysfunction can be detected using adenosine triphosphate (ATP) 
testing, while also investigating the effects of metabolic and/or myocardial 
microcirculatory abnormalities on the pathogenesis of cardiac autonomic 
nerve dysfunction in patients with type 2 diabetes mellitus (DM-2) in Japan. 
Methods: This prospective study was performed at the Division of Diabe- 
tology, Department of Internal Medicine, Toho University, Ohashi Hospital, 
Tokyo, Japan. Patients aged ___18 years with DM-2 with no abnormalities on electro- 
cardiography (ECG) or echocardiography were enrolled. An ATP thallium (T1)-201 
myocardial scintigraphy test (ATP test) and iodine (0-123 metaiodobenzyl- 
guanidine (MIBG) scintigraphy were performed. ATP was administered by con- 
tinuous IV infusion over 6 minutes at 0.16 mg/kg • min. Five minutes after the 
ATP infusion was started, T1-201 111 MBq IV was administered. Single-photon 
emission computed tomography (SPECT) imaging was begun immediately after 
the end of ATP infusion and was completed 3 hours after stress to show 
washout from stress to rest. 1-123 MIBG 111 MBq IV was administered. A planar 
image from the front side and a SPECT image (early phase) was obtained 15 to 
30 minutes later. After 3 hours, a planar image from the front side and a SPECT 
image (late phase) were obtained to show washout from stress to rest. The mean 
T1 washout rate (ATP-WR) and heart-to-mediastinum (H/M) ratio in the late-phase 
scintigraphic mages and the washout rate of MIBG (MIBG-WR) in the left ventri- 
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cle was determined. The correlations of these measurements with the mean val- 
ues of glycosylated hemoglobin (HbAlc) and fasting plasma glucose obtained from 
monthly measurements over the previous 6 and 24 months were determined. 
Results: A total of 25 patients were enrolled (13 men, 12 women; mean [SD] 
age, 59.86 [8.28] years). Significant negative correlations between both ATP-WR 
and MIBG-WR and HbAlc were found (r = -0.52 [P = 0.02] and -0.47 [P = 0.03], 
respectively). Although no correlation was found between ATP-WR values and 
the early phase H/M ratio, a significant positive correlation was observed 
between ATP-WR and H/M ratio (r = 0.54; P = 0.02). 
Conclusions: In the present study in Japanese diabetic patients without sub- 
jective signs of coronary artery disease and without abnormalities on ECG or 
echocardiography, ATP-WR, an indicator of myocardial blood flow, was corre- 
lated with myocardial sympathetic nerve dysfunction and 24-month glycemic 
control. However, sympathetic nerve dysfunction was not correlated with 
24-month glycemic ontrol. (Curr Ther Res Clin Exp. 2005;66:600-612) Copyright 
© 2005 Excerpta Medica, Inc. 
Key words: cardiac sympathetic nervous dysfunction, ATP T1-201 myocardial 
scintigraphy, 1-123 metaiodobenzylguanidine scintigraphy, glycemic ontrol. 
INTRODUCTION 
In diabetic patients, cardiac autonomic neuropathy, which is thought o be 
associated with sudden death and asymptomatic myocardial infarction, serves 
as an important factor affecting prognosis. 1 The results of recent studies have 
attracted researchers' attention. 2-4 These studies suggested a relatively poor 
prognosis in diabetic patients with cardiac autonomic neuropathy in the 
absence of clinically detectable micro- and macrovascular complications. Thus, 
autonomic function tests might provide a guide to prognosis. 
Whether cardiac autonomic neuropathy in diabetic patients is associated 
with neurovisceral metabolic disorder or myocardial microcirculatory disorder 
remains to be clarified. 
Isotopic myocardial blood flow scintigraphy may be one of the most useful 
methods of assessing myocardial microcirculatory disorder, but it does not allow 
a micro-level evaluation in patients with stenosis in the thick coronary arteries. 
Therefore, I performed adenosine triphosphate (ATP) thallium (T1)-201 myocardial 
scintigraphy 5 in patients with no abnormal findings on electrocardiography (ECG) 
performed uring rest and exercise to evaluate microcirculatory disorder based 
on the washout rates of T1. I also performed iodine 0)-123 metaiodobenzylguani- 
dine (MIBG) scintigraphy 5 to assess cardiac sympathetic nervous function. MIBG 
scintigraphy provides images of the presynapsis of cardiac sympathetic nerves, 
with excellent quantification capability and reproducibility. 5 
I assessed the correlations of cardiac autonomic neuropathy and myocardial 
microcirculatory disorder and glycemic ontrol. 6 Using ATP T1-201 and MIBG 
scintigraphy, I conducted the present study for the purposes of determining 
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whether cardiac sympathetic nerve dysfunction can be detected using ATP test- 
ing, while also investigating the effects of metabolic and/or myocardial micro- 
circulatory abnormalities on the pathogenesis of cardiac autonomic nerve dys- 
function in patients with type 2 diabetes mellitus (DM-2) in Japan. 
PATIENTS AND METHODS 
Male and female patients aged ___18 years with DM-2 who were seen at the 
Division of Diabetology, Department of Internal Medicine, Toho University, 
Ohashi Hospital, Tokyo, Japan, between February 1997 and September 2000 
were enrolled. Patients were excluded if they had poorly controlled hyperten- 
sion (systolic/diastolic blood pressure, ___160/___100 mm Hg), chest pain, and/or 
abnormal findings on ECG or echocardiography on rest or exercise. 
The study protocol was approved by the institutional review board at the 
hospital. Written informed consent was obtained from each patient. All patients 
who participated in the study were volunteers, and there was no compensation 
for participation. 
Study Design 
To assess cardiac sympathetic nerve function, ATP T1-201 myocardial scintig- 
raphy and 1-123 MIBG scintigraphy were performed. Patients arrived for their 
clinic visits at their assigned times and underwent routine examination for DM-2. 
ATP 7"1-201 Myocardial Scintigraphy 
While monitoring each patient's blood pressure, a catheter was inserted and 
ATP was administered by continuous IV infusion over 6 minutes at 0.16 mg/kg • min. 
Five minutes after the start of the ATP infusion, T1-201 111 MBq IV was adminis- 
tered and flushed with 10 mL of physiologic saline. Early phase single-photon 
emission computed tomography (SPECT) imaging was begun immediately after 
the ATP infusion was completed. Three hours later, to show washout from 
stress to rest (3 hours after stress), late-phase SPECT images were obtained. 
The mean washout rate of T1-201 in the left ventricle (ATP-WR) was calculated 
using a bull's-eye map created from 10 slices of short-axis SPECT images, as 
follows: 
ATP-WR = 
Count in early phase - Count in late phase 
Total count in early phase 
I-123 MIBG Scintigraphy 
After an interval of at least 3 days after ATP T1-201 myocardial scintigraphy, 
1-123 MIBG 111 MBq IV was administered to each patient at rest. A frontal pla- 
nar image and an early phase SPECT image were obtained 15 to 30 minutes later. 
Three hours later, to show washout from stress to rest (3 hours after stress), an 
additional frontal planar image and a late-phase SPECT image were obtained. 
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Using the planar images in the early and late phases, a heart-to-mediastinum 
(H/M) ratio, which indicates the MIBG uptake into the heart, was calculated. 7 A 
depressed H/M ratio (<2.0%) could indicate: (1) low density of the sympathetic 
nerves; (2) impaired uptake of MIBG into the sympathetic nerve terminals 
(uptake-i); and/or (3) impaired microcirculation. The 1-123 MIBG washout rate 
(MIBG-WR) in the entire left ventricle was calculated, using the region of inter- 
est (ROI) of the heart obtained from the frontal planar images in the early and 
late phases, as follows: 
MIBG-WR = 
ROI in early phase - ROI in late phase 
ROI in early phase 
The 3-day interval between scintigraphy studies took into account he tl/2 
values of the radionuclides, T1and I. The tolerability of the radioisotopes was 
not assessed because they have not been found to be associated with any clin- 
ically significant adverse reactions. 
SPECT Imaging 
A cardiofocal collimator (MuIti-SPECT3, Siemens Medical Systems, Hoffman 
Estates, Illinois) was used for SPECT imaging. The collimator otates 360:, with 
30 seconds per projection at each 5: angle. Reconstruction was performed at 
an energy peak of 70 to 80 KeV with a 20% window. The data were acquired in a 
125 x 125 matrix. 
Assessment of Glycemic Control 
Fasting plasma glucose (FPG) and glycosylated hemoglobin (HbAlc) values 
were determined within 1 month before and after ATP and MIBG scintigraphy. 
In each patient, means of monthly FPG and HbAlc values were calculated over 
6 and 24 months before scintigraphy. The last FPG and HbAI~ measurements were 
obtained at the last clinical check, within 2 weeks before the first scintigraphy. 
Based on the FPG and HbAI~ results, the following correlations were 
assessed: 
1. ATP-WR and H/M ratio; 
2. ATP-WR and MIBG-WR; 
3. ATP-WR and glycemic ontrol (FPG and HbAI~); and 
4. Glycemic ontrol, H/M ratio, and MIBG-WR. 
Tolerability 
Tolerability was assessed using blood pressure monitoring during scintigraphy. 
Statistical Analysis 
Correlation analyses were performed using simple linear regression, with 
StatView version 5 (SAS Institute Inc., Cary, North Carolina). P < 0.05 was con- 
sidered statistically significant. Data are expressed as mean (SD). 
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RESULTS 
Twenty-five patients were enrolled (13 men, 12 women; mean [SD] age, 59.86 
[8.28] years). The baseline characteristics of the patients are shown in the 
table. The mean (SD) duration of DM diagnosis was 8.82 (5.42) years. Sixteen 
patients received oral hypoglycemic agents, and 5 patients had previously 
received dietary therapy alone. Of the 16 patients who had received hypo- 
glycemic agents, 12 were treated with monotherapy with a sulfonylurea (SU); 4, 
with a combination of SU and an cz-glucosidase inhibitor; and 4, with intermedi- 
Table. Demographic and baseline clinical characteristics of the study 
patients (N = 25). 
Characteristic Value 
Age, mean (SD), y 59.86 (8.28) 
Sex, no. 
Male 13 
Female 12 
BMI, mean (SD), kg/m 2 20.91 (0.82) 
Smoking habit, no. 7 
Duration of diabetes diagnosis, mean (SD), y 8.82 (5.42) 
Previous treatment, no.* 
Oral hypoglycemic agent 16 
Sulfonylurea 12 
Sulfonylurea + ~-glucosidase inhibitor 4 
Intermediate 70/30 insulin 4 
Dietary 5 
FPG, mean (SD) of 1 month, mg/clL 168.2 (48.3) 
HbAlc , mean (SD) of 1 month, % 7.60 (1.11) 
HbAlc , mean (SD) of 6 months, % 8.10 (1.58) 
HbAlc , mean (SD) of 24 months, % 8.1 6 (1.83) 
Ejection fraction, mean (SD), % 65.32 (3.45) 
Complications, no. t 
Hyperlipidemia 14 
Nephropathy 13~ 
Retinopathy 11 § 
Neuropathyll 10 
Hypertension ql 9 
BMI = body mass index; FPG = fasting plasma glucose; HbAlc = glycosylated 
hemoglobin. 
*Some patients received >1 treatment. 
tSome patients had >1 complication. 
~Eight patients had microalbuminuria (creatinine, 30-300 pg/mL) and 5 had pro- 
teinuria (creatinine, >300 pg/mL). 
§Six patients had simple retinopathy and 5 had preproliferative r tinopathy. 
IlWith absent endon reflex or subjective symptoms. 
qlSystolic/diastolic blood pressure_>140/_>90 mm Hg. 
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ate 70/30 insulin. Diabetic omplications atbaseline were as follows: hyperlipid- 
emia, 14 patients; nephropathy, 13 (8 with microalbuminuria and 5 with pro- 
teinuria); retinopathy, 11 (6 with simple retinopathy and 5 with preproliferative 
retinopathy); and neuropathy (with absent endon reflex or subjective symp- 
toms), 10 patients. Mean (SD) FPG and HbAlc values at 1 month before or after 
ATP and MIBG scintigraphy were 168.2 (48.3) mg/dL and 7.60% (1.11%), respec- 
tively. Mean (SD) HbAI~ values over 6 and 24 months before the study were 
8.10% (1.58%) and 8.16% (1.83%), respectively. 
ATP and MIBG Scintigraphy 
On ATP scintigraphy, no changes on ECG were observed uring the ATP treat- 
ment. No local loss was observed in the early or late-phase images on ATP or 
MIBG SPECT imaging, indicating no abnormalities in blood flow or sympathetic 
nerve distribution. Mean (SD) ATP-WR was 36.6% (10.0%) (normal range, 
40%-50%). Mean (SD) MIBG H/M ratio in the early and late-phase images were 
2.01% (0.20%) and 2.05% (0.29%), respectively (normal range, 2%-3%). Figures 1 
and 2 show MIBG activity in 2 patients. Although no correlation was found 
between ATP-WR values and the early phase H/M ratio, a positive correlation was 
found between ATP-WR and late-phase H/M ratio (r = 0.54; P = 0.02) (Figure 3). 
The mean (SD) MIBG-WR was 34.0% (6.7%) (normal range, 20%-30%). A negative 
correlation was observed between ATP-WR and MIBG-WR (r = -0.52; P = 0.02) 
(Figure 4). 
Glycemic Control 
Mean (SD) FPG and HbAlc values at 1 month before and after ATP and MIBG 
scintigraphy were 168.2 (48.3) mg/dL and 7.60% (1.11%), respectively. Although 
no correlation was found between FPG or HbAlc at the time of the treatment 
(within 1 month), a negative correlation was found between ATP-WR and mean 
HbAI~ during the 6 months before the study (r = -0.47; P = 0.03), and between 
ATP-WR and mean HbAI~ during the previous 24 months (r = -0.51; P = 0.02) 
(Figure 5). 
No correlation was found between either MIBG H/M ratio (early and late- 
phase images) and MIBG-WR and either FPG or HbAI~ within 1 month of treatment. 
No correlation was found between mean HbAI~ during the 6 and 24 months 
before scintigraphy. 
Tolerability 
None of the patients had abnormal blood pressure values during the study. 
DISCUSSION 
Diabetic neuropathy, retinopathy, and nephropathy are complications unique 
to DM. Although the latter two occur many years after the onset of DM, diabetic 
neuropathy often occurs in a relatively early stage of the disease. Despite the 
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Figure 1. Myocardial metaiodobenzylguanidine (MIBG) activity in a diabetic patient 
with preserved thallium (TI)-201 washout. (A) Polar maps of TI-201 activity 
in the left ventricle myocardium with adenosine triphosphate stress and at 
rest (3 hours after stress) (left, early phase; right, late phase). There was no 
perfusion defect. The lower panels show polar map of TI-201 washout from 
stress to rest (3 hours after stress). The mean washout rate of TI-201 was 
49.5%. (B) Iodine-123 MIBG myocardial scintigraphy delayed planar ante- 
rior image of the chest obtained 4 hours after IV injection of nuclear agent. 
The mean isotope count at region of interest over the heart (H) and medi- 
astinum (M) were measured, and the H/M ratio was 2.8. The MIBG washout 
rate from early (15 minutes after injection) to delayed imaging was 32.4%. 
high prevalence of neuropathy in patients with DM, research concerning this 
complication seems to lag behind that concerning diabetic ret inopathy and 
nephropathy due to less awareness of a deter iorated quality of life and a poor 
survival prognosis. In addition, the mechanisms of structural and physiologic 
disorders associated with diabetic neuropathy have not been clarified. 8 Based 
on a l iterature search of MEDLINE (key terms: diabetic neuropathy, peripheral 
neuropathy, and autonomic neuropathy; ears: 1970-2004), although many cases 
of peripheral neuropathy, such as motor and sensory  nerve dysfunction, have 
been reported, reports of autonomic neuropathy are relatively limited. Only a 
few studies have assessed whether these dysfunctions affect each other, and if 
they do, how they interact with each other. In addition, a method of assessment 
of early autonomic neuropathy has not yet been established. 
Possible causes of neuropathy include a reduced number of nerve fibers, 
wallerian degeneration, and the slow reproduction of nerve fibers, which are 
considered to be associated with hyperglycemia. 9,1° It has been reported that 
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Figure 2. Myocardial metaiodobenzylguanidine (MIBG) activity in a diabetic patient 
with preserved thallium (TI)-201 washout. (A) Polar maps of TI-201 activity 
in the left ventricle myocardium with adenosine triphosphate stress and at 
rest (3 hours after stress) (left, early phase; right, late phase). There was no 
perfusion defect. The lower panels show polar map of TI-201 washout from 
stress to rest (3 hours after stress). The mean washout rate of TI-201 was 
17.2% and diffusely slow compared with that of the patient in Figure 1. 
(B) Iodine-123 MIBG myocardial scintigraphy delayed planar anterior image 
of the chest obtained 4 hours after IV injection of nuclear agent. The mean 
isotope count at region of interest over the heart (H) and mediastinum (M) 
were measured, and the H/M ratio was 2.1. The MIBG washout rate from 
early (15 minutes after injection) to delayed imaging was 44.2%. These 
findings show a decreased uptake of MIBG to the myocardial sympathetic 
nerve ends and increased washout compared with that of the patient in 
Figure 1, suggesting impaired function of the cardiac sympathetic nerves. 
hyperglycemia induces metabolic abnormalities, uch as intracellular accumu- 
lation of sorbitol, 1°'11 accelerated production of advanced glycation end prod- 
ucts, 1°,12 and abnormal protein kinase C activity. 13 Researchers have started to 
investigate the involvement of vascular insufficiency in the development and 
progress of neuropathy. 9 A cardiac microcirculatory disorder might be associ- 
ated with cardiac autonomic neuropathy. 
Diabetic patients with coronary artery disease (CAD) are generally consid- 
ered to have a poorer prognosis compared with nondiabetic patients with CAD 
for various reasons, including the following: high risk for cardiac failure14; dif- 
fuse coronary artery lesions extending to the peripheral branches, which can 
cause cardiac failure15; and the presence of diabetic cardiomyopathy. 16 Some 
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Figure 3. Correlation of adenosine triphosphate thallium-201 washout rate (ATP-WR) 
and iodine-123 metaiodobenzylguanidine (MIBG) heart-to-mediastinum (H/M) 
ratio (r-- 0.54; P-- 0.02). 
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Figure 4. Correlation of adenosine triphosphate thallium-201 washout rate (ATP-WR) 
and iodine-123 metaiodobenzylguanidine washout ratio (MIBG-WR) (r-- 
-0.52; P-- 0.02). 
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Figure 5. Correlation of adenosine triphosphate thallium-201 washout rate (ATP-WR) 
and glycemic control as measured by the mean of monthly glycosylated 
hemoglobin (HbAlc) concentrations over 24 months before scintigraphy 
(r = -0.51; P = 0.02). 
patients have DM-related cardiac dysfunction i which a diastolic filling is inhib- 
ited by deteriorated wall motion of the left ventricle (even without significant 
stenosis on coronary angiography at the first hospital visit), suggesting a role 
for sympathetic nerve dysfunction in cardiac dysfunction. 17
Ischemic heart disease (IHD) is the most frequently reported cause of DM 2- 
related death. For this reason, and because of the difficulty in detecting tho- 
racic symptoms in diabetic patients, physicians are encouraged to examine 
whether IHD is developing without subjective symptoms. Without subjective 
symptoms, patients might not be aware of the disease, or patients might have 
difficulty understanding the necessity of diagnostic assessments, especially if
these assessments include invasive testing. 5 Furthermore, in many diabetic 
patients, the presence of retinopathy and/or nephropathy might prevent hem 
from undergoing exercise testing. 5 For these reasons, I consider ATP T1-201 
myocardial scintigraphy, a drug-loading test, to be most suitable for the detec- 
tion of IHD in diabetic patients. ATP T1-201 scintigraphy and nuclear methods 
using a 13N-ammonia tracer are useful for assessing myocardial blood flow. A dif- 
fuse slow washout of T1 in the cardiac muscle generally indicates triple vessel 
disease. However, in patients with no stenosis on coronary angiography, a dif- 
fuse slow washout of T1 in the cardiac muscle might indicate cardiac myocyte 
dysfunction or myocardial microcirculatory abnormality. 
In conventional ssessment ofcardiac autonomic neuropathy, the RR interval 
is assessed using ECG 18 or 24-hour ambulatory blood pressure monitoring, and 
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Ewing's test results are quantified. 19In recent years, 1-123 MIBG scintigraphy 
using nuclear medical techniques has been used for the assessment of cardiac 
sympathetic nerve function. MIBG, considered to have uptake, storage, and 
release mechanisms similar to those of norepinephrine, is mainly taken into 
norepinephrine-retaining granules by the norepinephrine r uptake mechanism 
(uptake-i) at the sympathetic nerve endings, thus allowing them to remain there 
without any metabolism for a relatively long period of time. Therefore, reuptake 
by uptake-1 is thought o reflect he distribution and function of the sympathetic 
nerves. MIBG allows imaging of sympathetic nerve activity. 6 Increased MIBG-WR 
indicates that MIBG taken into the secretory granule tends to easily disappear 
over time. Diabetic patients lacking MIBG uptake are suspected to have some 
dysfunction that results in a decreased ability to store and maintain orepineph- 
rine within the granule. 2° This decreased ability might be associated with a 
microcirculatory disorder, based on the fact that the sympathetic nervous ys- 
tem regulates myocardial contractile force and microvascular tonus. 21 
Although it has been found that metabolic and/or microcirculatory abnormal- 
ities involve extracardiac autonomic or peripheral nerve disorders, 22-24 the pur- 
pose of the present study was to determine whether these abnormalities play a 
role in the pathogenesis of cardiac autonomic nerve dysfunction. I found a cor- 
relation between the 2 nuclear medical scintigraphic methods and between the 
results of ATP testing and glycemic ontrol over 24 months. These results sug- 
gest that sustained hyperglycemia does not appear to have a direct relation to 
the autonomic nervous ystem but might be related to myocardial microcircula- 
tory abnormalities, which, in turn, are related to autonomic nerve dysfunction. 
These results suggest hat microcirculatory disorders related to poor glycemic 
control might, in turn, contribute to cardiac sympathetic nerve dysfunction. 
In diabetic patients with poor glycemic ontrol over the long term, IHD and 
cardiac autonomic neuropathy might be suspected, even if no abnormalities are 
found on resting ECG or echocardiography. Diabetic patients undergoing ATP 
testing for IHD and having a slow T1 washout might have some degree of 
myocardial sympathetic nerve dysfunction. Therefore, these patients hould be 
followed up carefully to provide appropriate hypoglycemic treatment. 
I cannot rule out the possibility of IHD in all of the patients in the present 
study because I did not perform coronary angiography. However, with the high 
sensitivity of the nuclear medical testing, I do not believe that I failed to detect 
significant stenosis. 5 As a result, I suggest hat ATP T1-201 scintigraphy might 
have an important role in assessing cardiac function in diabetic patients. In 
addition, the correlation between ATP-WRs and long-term glycemic control 
(HbAlc over the previous 24 months) lends support o the importance ofglycemic 
control from the early stages of DM. 
The present study had the following limitations: no sympathetic tests or 
coronary angiography were performed, a small sample size was used, and no 
controls were provided. Further investigations are scheduled, including sympa- 
thetic tests and coronary angiography using a larger sample size. 
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The findings from this study reaffirm the importance of glycemic control in 
diabetic patients. Diabetic patients with a slow T1 washout rate could be com- 
pl icated with myocardial  microc i rcu latory  abnormal i t ies and cardiac sympa- 
thetic nerve dysfunct ion even without any known coronary  arterial lesions. 
Therefore, in these patients, careful attention should be paid to preventing car- 
diac failure and sudden death. 
CONCLUSIONS 
In the present study in Japanese diabetic patients without subjective signs of 
CAD and without abnormalit ies on ECG or echocardiography, ATP-WR, an indi- 
cator of myocardial blood flow, was correlated with myocardial sympathet ic 
nerve dysfunction and 24-month glycemic ontrol. However, sympathet ic  nerve 
dysfunction was not correlated with 24-month glycemic control. 
ACKNOWLEDGMENTS 
The author thanks Kazuteru Oi, MD, Division of Diabetology, Department of 
Internal Medicine, Toho University, Ohashi Hospital, Tokyo, Japan, for his con- 
t inuous guidance on performing this study. The author is also grateful to Masao 
Moroi, MD, of the Division of Cardiovascular Medicine, Department of Internal 
Medicine, Toho University, Ohashi Hospital, Tokyo, Japan, for his advice. 
REFERENCES 
1. Ewing D J, Campbell IW, Clarke BE The natural history of diabetic autonomic neu- 
ropathy. Q J Med. 1980;49:95-108. 
2. Rathmann W, Ziegler D, Jahnke M, et al. Mortality in diabetic patients with cardiovas- 
cular autonomic neuropathy. Diabet Med. 1993;10:820-824. 
3. Ewing D J, Campbell IW, Clarke BE Mortality in diabetic autonomic neuropathy. Lancet. 
1976;1:601-603. 
4. Stevens M J, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation i  dia- 
betes: Implications for enhanced cardiovascular risk. Circulation. 1998;98:961-968. 
5. Tamaki N, ed. Basis and Clinical of Cardiac Nuclear Medicine--Modern Methods and 
Clues to Clinical Applications of Cardiac Nuclear Medicine [in Japanese]. Tokyo, Japan: 
Medicalsens; 1998. 
6. Mantysaari M, Kuikka J, Mustonen J, et al. Noninvasive detection of cardiac sympa- 
thetic nervous dysfunction in diabetic patients using [123I] metaiodobenzylguani- 
dine. Diabetes. 1992;41:1069-1075. 
7. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodoben- 
zylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471-477. 
8. Baba M. Diabetic Neuropathy." Diagnosis and Examination of Diabetic Neuropathy [in 
Japanese]. Tokyo, Japan: Gendaiiryo-sha; 2001:45-55. 
9. Green DA, Sima AAF, Stevens M J, et al. Complications: Neuropathy, pathogenic con- 
siderations. Diabetes Care. 1992;15:1902-1925. 
611 
CURRENT THERAPEUTIC RESEARCH 
10. Clark CM Jr, Lee DA. Prevention and treatment of the complications ofdiabetes mel- 
litus [published correction appears in N Engl J Med. 1995;333:810]. N Engl J Med. 
1995;332:1210-1217. 
11. Green DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium-potassium- 
ATPase in the pathogenesis of diabetic complications. N Engl J Med. 1987;316:599- 
606. 
12. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue 
and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315- 
1321. 
13. Muller HK, Kellerer M, Ermel B, et al. Prevention by protein kinase C inhibitors of 
glucose-induced insulin-receptor tyrosine kinase resistance in rat fat cells. Diabetes. 
1991;40:1440-1448. 
14. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival 
following myocardial infarction in men vs women. The Framingham Study [pub- 
lished correction appears in JAMA. 1989;261:1884]. JAMA. 1988;260:3456-3460. 
15. Dortimer AC, Shenoy PN, Shiroff RA, et al. Diffuse coronary artery disease in diabetic 
patients: Fact or fiction? Circulation. 1978;57:133-136. 
16. Butler R, Macdonald TM, Struthers AD, Morris AD. The clinical implications of dia- 
betic heart disease. EurHeartJ. 1998;19:1617-1627. 
17. Kahn JK, Zola B, Juni JE, Vinik AI. Radionuclide assessment of left ventricular dias- 
tolic filling in diabetes mellitus with and without cardiac autonomic neuropathy. 
JAm Coil Cardiol. 1986;7:1303-1309. 
18. Wheeler T, Watkins PJ. Cardiac denervation i diabetes. BMJ. 1973;4:584-586. 
19. Ewing D J, Martyn CN, Young R J, Clarke BE The value of cardiovascular utonomic 
function tests: 10 Years experience in diabetes. Diabetes Care. 1985;8:491-498. 
20. Ito T, Hatakeyama S, Azuma S, et al. Evaluation of cardiac sympathetic nerve dysfunc- 
tion using 123 1 metaiodobenzylguanidine (MIBG) scintigraphy in patients with non- 
insulin-dependent diabetes mellitus [in Japanese]. Kinki Central Hospital MedJ. 1998; 
9:9-14. 
21. Taniguchi I, Mochizuki M. Microcirculatory disorder of diabetic heart. Heart View. 
1999;3:621-626. 
22. Hotta N. Molecular biology of microangiopathy in diabetes mellitus. In: Advances in 
Diabetology--A Guide to Regimens for Diabetes Mellitus [in Japanese]. Tokyo, Japan: 
Shindantochiryo-sha; 2000:190-224. 
23. Hotta N. What account etiologically for angiopathy? Known facts and future tasks. In: 
Advances in Diabetology--A Guide to Regimens for Diabetes Mellitus [in Japanese]. 
Tokyo, Japan: Shindantochiryo-sha; 2000:97-105. 
24. Vinki AI, Pittenger GL, McNitt P, Stansberry KB. Diabetic neuropathies: An overview 
of clinical aspects, pathogenesis, and treatment. In: LeRoith D, Taylor SI, Olefsky JM, 
eds. Diabetes Mellitus: A Fundamental and Clinical Text. 2nd ed. Philadelphia, Pa: 
Lippincott Williams & Wilkins; 2000:910-934. 
Address correspondence to: Hiromi Komori, MD, Division of Diabetology, 
Department of Internal Medicine, Toho University, Ohashi Hospital 2-17-06 
Ohashi Meguro-ku, Tokyo, Japan. E-mail: koi@oha.toho-u.ac.jp 
612 
